Rockwell Medical Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Financial Results

Core Insights - Rockwell Medical, Inc. reported significant revenue growth and improved financial metrics for Q4 and full-year 2025, indicating a strong operational performance and a focus on profitability [2][7] - The company achieved a gross margin of 22% in Q4 2025, a notable increase from 14% in Q3 2025, reflecting enhanced operational efficiencies and cost reductions [2][7] - Rockwell Medical aims to focus on revenue growth, increased profitability, and portfolio diversification as key strategic areas for 2026 [2] Financial Highlights - Preliminary net sales for Q4 2025 are expected to be approximately $18.6 million, while full-year 2025 net sales are projected at around $69.5 million [7] - Cash flow from operations for Q4 2025 is anticipated to be approximately $2.3 million, marking the second cash flow positive quarter in 2025 [7] - Cash and cash equivalents, along with investments available-for-sale, are expected to increase to approximately $25 million by December 31, 2025 [7] Company Overview - Rockwell Medical specializes in developing, manufacturing, and distributing hemodialysis products for dialysis providers globally, with a mission to deliver high-quality products and exceptional customer service [5] - The company is recognized as a Great Place to Work for three consecutive years (2023, 2024, 2025) and has been named among Fortune's Best Workplaces in Manufacturing & Production for 2024 and 2025 [5] - Rockwell Medical is committed to innovative growth strategies that enhance its product offerings and operational processes, aiming to provide significant value to the healthcare system and improve the lives of hemodialysis patients [5]